| News/Press |
 Here
are the latest updates and press releases concerning NewLink Genetics.
Please check back frequently to see the latest developments at NewLink
Genetics. We will update this page as often as possible, however, if
you have an immediate question, please do not hesitate to contact the
investor relations office at (515) 296-3530.
- IND filed for IMT, our first small molecule drug candidate.
- New sites to participate on Newlink clinical trials.
- Northwestern University (HyperAcute Lung Cancer vaccine).
- University of Louisville, Kentucky (HyperAcute Pancreatic Cancer vaccine).
- Patient enrollment began (Phase I) for 1MT IDO-inhibitor small molecule program
|
|
